Article info
Clinical science
Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
- Correspondence to Dr Jeffrey S Heier, Department of Retina, Ophthalmic Consultants of Boston, 50 Staniford Street, Suite 600, Boston, MA 02114, USA; jsheier{at}eyeboston.com
Citation
Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
Publication history
- Received March 5, 2013
- Revised April 26, 2013
- Accepted May 20, 2013
- First published June 13, 2013.
Online issue publication
July 10, 2013
Article Versions
- Previous version (13 June 2013).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions